Tempus confirmed it has acquired the pharmacogenetics assets of OneOme, the Mayo Clinic spinout that abruptly ceased operations in November. The assets include OneOme’s RightMed PGx test and partnerships with dozens of health systems; Tempus did not disclose financial terms. Sources described the acquisition as primarily an opportunity to capture OneOme’s book of business and clinical partnerships rather than core IP. Tempus already offers PGx testing and expects the OneOme assets to accelerate market penetration and expand clinical relationships. The move follows OneOme’s sudden shutdown and highlights consolidation in the clinical‑genomics services market as financially stressed specialists are absorbed by larger diagnostics platforms.